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Synaptic activityThe mammalian target of rapamycin (mTOR) is involved in the regulation of learning and memory. Recently,
rapamycin has been shown to be neuroprotective in models for Alzheimer's disease in an autophagy-
dependent manner. Here we show that rapamycin exerts neuroprotection via a novel mechanism that involves
presynaptic activation. Rapamycin increases the frequency of miniature excitatory postsynaptic currents and
calcium transients of rat hippocampal primary neurons by a mechanism that involves the up regulation of SV2,
a presynaptic vesicular protein linked to neurotransmitter release. Under these conditions, rapamycin-treated
hippocampal neurons are resistant to the synaptotoxic effect induced byAβ oligomers, suggesting that enhancers
of presynaptic activity can be therapeutic agents for Alzheimer's disease.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The mammalian target of rapamycin (mTOR), an evolutionarily
conserved serine/threonine protein kinase, regulates protein synthesis
and macroautophagy, among other processes [1,2]. mTOR is involved
in two distinct enzymatic complexes with different functions, a
rapamycin-sensitive complex (TORC1) and a rapamycin-insensitive
complex (TORC2). mTOR regulates local protein synthesis at the synap-
ses [3] required for the formation, maturation, and function of new
spine synapses [4] that canmodulate learning andmemory [5,6]. More-
over, mTOR-dependent local axonal autophagy can rapidly regulate
presynaptic structure and function [7], and autophagy also positively
regulates development of theDrosophila melanogaster larval neuromus-
cular junction [8].
Rapamycin is a macrolide antibiotic and immunosuppressant drug
used to prevent rejection in organ transplantation produced by the
bacterium Streptomyces hygroscopicus [9], whose mechanism of actione; mTOR, mammalian target of
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s.opazo@ﬂorey.edu.auis to inhibit TORC1 activity. It has been shown that long-term treatment
with rapamycin increases the lifespan in mice, possibly by delaying
aging [10,11], an effect correlated with decreased protein biosynthesis
and autophagy activation [12]. In the central nervous system (CNS),
rapamycin shows beneﬁcial effects in survival and neuronal plasticity,
thus it could contribute to memory improvement in neurodegenerative
disorders [4,12–15]. Accordingly, rapamycinwas shown to have beneﬁ-
cial effects in vivo [16]. The pathological hallmarks of Alzheimer's
disease (AD) are the formation of extracellular senile plaques, mainly
composed of amyloid-β (Aβ) peptide, and intracellular neuroﬁbrillary
tangles containing hyperphosphorylated tau protein [12]. Aβ peptide
is generated by sequential proteolysis of amyloid-β precursor protein
(APP), with Aβ1–42 being themost toxic form of the peptide [12,17]. Re-
cent evidence shows that rapamycin reduces Aβ levels and abolishes AD
progression in a transgenic mouse model of the disease by stimulating
autophagy [16]. In the same vein, Aβ can activate the mTOR pathway,
which is blocked by rapamycin [18,19].
Considering that chronic application of Aβ induces neurotransmis-
sion failure [20,21], we examined whether rapamycin can abolish the
synaptic deﬁcit induced by Aβ. We investigated the effect of rapamycin
onminiature postsynaptic currents, calcium transients and the levels of
the presynaptic protein SV2 using patch clamp, quantitative calcium
recordings, immunoﬂuorescence and Western blot, respectively. We
report that rapamycin, in chronic conditions (48 h), enhances the
synaptic transmission affecting mainly the presynaptic site as expressed
by upregulation of SV2 levels. In agreement with this ﬁnding, rapamycin
increased the frequency of calcium transients andminiature postsynaptic
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synaptotoxic effects induced by Aβ oligomers.
Taken together, this data indicates that inhibition of the mTOR
pathway by rapamycin enhances synaptic transmission making
neurons more resistant to the synaptotoxic effects of Aβ oligomers.
2. Materials and methods
2.1. Peptide Aβ1–42 preparation
Human synthetic Aβ1–42 peptide was purchased from GenicBio
(China). Aβ1–42 was dissolved in 100% hexaﬂuoroisopropanol
(10 mg/mL) and stored in aliquots at−20 °C. The Aβ1–42 aggregation
and the formation of Aβ1–42 oligomers were carried out as previously
described [22]. Brieﬂy, for the preparation of Aβ1–42 oligomers, aliquots
of 5 μL of Aβ1–42 (10 mg/mL) were added to 137.5 μL ultrapure water
(ﬁnal Aβ1–42 concentration 80 μM) in an Eppendorf tube. After 15 min
of incubation at room temperature (~22 °C), the samples were
centrifuged at 14,000 g for 15 min, and the supernatant fraction was
transferred to a new Eppendorf tube. To form Aβ1–42 oligomers, the
samples were stirred at 500 rpm using a Teﬂon-coated micro-stir bar
for 24–48 h at room temperature (~22 °C). The formation of oligomers
was monitored by turbidity at 400 nm and the structure of oligomers
was conﬁrmed by electron microscopy (data not shown) as previously
described [22]. Aβ1–42 oligomers were used immediately after their
preparation or stored at 4 °C (up to 1 h) until used.
2.2. Hippocampal cultures and treatments
Hippocampal neurons were obtained from 18-day-old Sprague–
Dawley rat embryos as previously described [23]. The primary hippo-
campal cultures were maintained in a neuronal feeding medium
consisting of 90% minimal essential medium (HyClone, USA), 5% heat-
inactivated horse serum (HyClone, USA), 5% fetal bovine serum
(Gibco, USA), and a mixture of nutrient supplements. The cultures
were treated at 14–15 DIV with 1 μM rapamycin for 48 h at 37 °C and
5% CO2 alone or in the presence of 500 nM Aβ oligomers [20]. Animal
care and protocols were in accordance with the National Institutes of
Health recommendations and approved by the Ethics Committee at
the University of Concepcion.
2.3. Patch clamp recordings
Patch pipettes (3–5 MΩ) were prepared from ﬁlament-containing
borosilicate micropipettes. Currents were measured with the whole
cell patch clamp technique at a holding potential of−60 mV using an
Axopatch 200B ampliﬁer (Axon Instruments). The data were displayed
and stored using a 1322A Digidata acquisition board and analyzed with
electrophysiological software (Axon Instruments). The external solu-
tion contained 150 mM NaCl, 5.4 mM KCl, 2.0 mM CaCl2, 1.0 mM
MgCl2, 10 mM glucose, and 10 mM HEPES (pH 7.4, 330 mOsmol). The
standard internal solution in the patch pipette contained 120 mM
KCl, 4.0 mM MgCl2, 10 mM BAPTA, and 2.0 mM Na2-ATP (pH 7.4,
310 mOsmol). Miniature postsynaptic currents were isolated by the
addition of TTX (50–100 nM; Alomone Labs, Israel) and were recorded
in 2-minute segments. The data were analyzed with the MiniAnalysis
8.0 program (Synaptosoft, Inc., Leonia, NY) to obtain mean averages of
peak amplitude and frequency.
2.4. Western blot
Standard Western blotting procedures were followed [24]. Equal
amounts of protein were separated on 10% SDS-polyacrylamide gels.
Protein bandswere transferred onto nitrocellulosemembranes, blocked
with 5% nonfat milk, and incubated with primary antibodies using the
following concentrations: 1:1000 anti-SV2 (Developmental StudiesHybridoma Bank, Iowa City, IA), and 1:5000 anti-α-tubulin (Sigma,
USA). Bands were visualized with the ECL Plus Western blotting detec-
tion system (PerkinElmer, USA) and the membranes were revealed in
the equipment Odyssey (Li-cor Bioscience, USA). Quantiﬁcation of the
signals was made with the Image Studio Version 1.1 program, and
α-tubulin was used as an internal control for the experiments.
2.5. Calcium imaging
Neuronswere loadedwith 5 μMFluo-4 AM (Molecular Probes, USA)
for 20 min at 37 °C. The neurons were then washed twice with DPBS
(1X) and incubated for 20 min at 37 °C. The cells were mounted in a
perfusion chamber that was placed on the stage of an inverted ﬂuores-
centmicroscope (Eclipse TE; Nikon) equipped with a xenon lamp and a
40× objective (22–24 °C). The cells were brieﬂy illuminated (200 ms)
using a computer-controlled Lambda 10–2 ﬁlter wheel (Sutter Instru-
ments). Regions of interest (ROI) were simultaneously selected on neu-
ronal soma emitting Fluo-4 ﬂuorescence (excitation 480 nm, emission
510 nm) in an optical ﬁeld having usually more than 10 cells. Images
were collected at 1 s intervals during a continuous 200 second period.
The recordings were obtained with an EMCCD iXon+ 16 bit camera
(Andor, Belfast, Northern Ireland) and both the ﬁlter control
and image capture were performed by the software Workbench 6.0
(INDEC BioSystems, USA).
2.6. Immunoﬂuorescence
Control and treated hippocampal neurons were ﬁxed for 10 min
with methanol and permeabilized with 0.1% Triton X-100 in
phosphate-buffered saline (PBS). Nonspeciﬁc immunoreactivity was
blocked with 10% horse serum for 30 min at room temperature
(22–24 °C). Monoclonal anti-SV2 antibody (1:200, Developmental
Studies Hybridoma Bank, Iowa City, IA) and polyclonal anti MAP2
(1:200, Santa Cruz Biotechnology, CA, USA) antibody was incubated
overnight followed by incubation with an anti-mouse secondary anti-
body conjugated with FITC (1:200; Jackson ImmunoResearch Laborato-
ries) and anti-rabbit secondary antibody conjugated with Cy3 (1:200;
Jackson ImmunoResearch Laboratories), respectively, for 1 h at room
temperature (22–24 °C). The samples were mounted in ﬂuorescent
mounting medium (DAKO, USA) for microscopic analysis.
2.7. Fluorescence measurements and epiﬂuorescence microscopy
FITC and Cy3 immunoﬂuorescence were visualized using a Nikon
Inverted Microscope Eclipse TE300 (60X, oil immersion, NA 1.4) with
Argon (488 nm) and He–Ne (543 nm) lasers for FITC and Cy3, respec-
tively. After acquisition, images were processed with ImageJ (NIH,
Maryland, USA).
2.8. Data analysis
Statistical analyseswere performed usingGraphPad Prism (GraphPad,
San Diego, CA, USA). The values are expressed as mean ± S.E.M. for 3 or
more independent experiments. Statistical differences were determined
using Student's t test or one-way ANOVA with Bonferroni post test.
p b 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Chronic effects of rapamycin on mEPSCs
Previous studies have shown that rapamycin increases the life span
[10,11], as well as the memory parameters in different animal models
[4,14]. In agreement with this, acute inhibition of mTOR by rapamycin
affects synaptic plasticity and the long-term potentiation in hippocam-
pal neurons by presynaptic and postsynaptic mechanisms, respectively
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cultured primary neurons. Thus, to evaluate the chronic effects of
rapamycin on the neuronal network, we used the whole cell patch
clamp technique (−60 mV) to determine the chronic effects of
rapamycin on miniature postsynaptic currents in primary hippocampal
neuron cultures. All recordings were obtained in the presence of
50–100 nM TTX in order to inhibit action potentials [23]. As shown in
Fig. 1, we found that the frequency of miniature postsynaptic currents
were signiﬁcantly higher after chronic administration (48 h) of
rapamycin (1 μM) as compared to control (Control, 0.633 ± 0.144 Hz,
n = 14 vs rapamycin, 1.610 ± 0.250 Hz, n = 10; p b 0.01) (Fig. 1A,B).
However, no signiﬁcant differences were observed in the amplitude of
the miniature postsynaptic currents (control, 26 ± 1.0 pA, n = 14 vs
rapamycin, 28 ± 1.2 pA, n = 10) (Fig. 1C). These results indicate that
chronic application of rapamycin enhances neurotransmission in hippo-
campal neurons by increasing the release of neurotransmitters from
presynaptic sites without apparent changes in postsynaptic receptors.
Next, we evaluated the effects of rapamycin on calcium transient
currents as deﬁned by their TTX sensitivity [26]. Spontaneous calcium
transients were measured with the Fluo4-AM probe allowing us to
assess the changes in intracellular calcium as reﬂected by synaptic and
neuronal network activity. As shown in Fig. 2, rapamycin (1 μM; 48 h)
signiﬁcantly increased the frequency of transient calcium currents in
hippocampal neurons (control: 100 ± 4% Hz, n = 58 vs rapamycin:
314 ± 7% Hz, n = 73; p b 0.001). These results suggest that rapamycin
increased the exocytosis of synaptic vesicles at the synaptic site in
agreement with the observed changes in the frequency of miniature
postsynaptic currents (Fig. 1). To evaluate whether these changes in
presynaptic activity correlated with changes in presynaptic or postsyn-
aptic structural components, we examined the effect of rapamycin on
the levels of the synaptic vesicle protein SV2 as a presynaptic marker
and PSD95 as a postsynaptic marker. The results obtained by Western
blot (Fig. 3A) showed an increase in the levels of SV2 in the presence
of rapamycin (control, 100 ± 9% vs rapamycin, 140 ± 9%; p b 0.05),
but no differences were found in the levels of PSD95 (control, 100 ±Control 
Rapamycin
2s 
A 
Fig. 1. Effect of rapamycin on synaptic activity of primary hippocampal neurons. (A) Representat
chronic rapamycin treatment (48 h; 1 μM) inhippocampal neurons. (B, C) The bars show the eff
in “A”. The values are mean ± SEM obtained from the indicated number of neurons. ** p b 0.017% vs rapamycin, 97 ± 48%), conﬁrming the presynaptic effect of
rapamycin observed in the electrophysiological analyses. The increase
in SV2 protein levels was corroborated by immunoﬂuorescence that
revealed a marked increase in SV2 immunoreactivity in rapamycin-
treated neurons as compared to controls (Fig. 3B). Together, these
results indicate that chronic application of rapamycin enhances the pre-
synaptic activity of hippocampal neurons and that the upregulation of
the presynaptic SV2 protein component may be involved in this effect.
3.2. Rapamycin protects against synaptotoxicity induced by Aβ oligomers
Anearly feature of AD is the synaptic failure that precedes hippocam-
pal neurodegeneration and neuronal loss [27]. It has been reported that
presynaptic proteins such as SV2, SNAP-25, synaptophysin, and synap-
totagmin are reduced in AD brains as well as in primary hippocampal
neurons exposed to Aβ oligomers [20,28–30]. Recent evidence suggests
that the pharmacological inhibition of themTOR pathway by rapamycin
decreases the cognitive deﬁcits in a mousemodel of AD and reduces the
levels of Aβ peptide [13,16,31,32]. Considering these reports, we quanti-
tatively assessed the effect of Aβ oligomers on SV2 levels in the presence
of rapamycin by Western blot (Fig. 4A). Our results demonstrated that
rapamycin prevented the reduction of SV2 levels induced by Aβ oligo-
mers (Control 107 ± 6%; Aβ 55 ± 10%; Aβ + rapamycin100 ± 14%;
rapamycin 154± 5%, p b 0.05). These results suggest that the upregula-
tion of SV2 may be involved in the neuroprotective effect of rapamycin
against Aβ oligomer-induced synaptotoxicity.
In addition, we determined the effect of rapamycin on the synaptic
failure induced by Aβ oligomers on the frequency of miniature postsyn-
aptic currents usingwhole cell patch clamp (−60mV; TTX 100 nM). As
previously described, chronic application of Aβ oligomers reduced the
synaptic activity of hippocampal neurons in culture [20]. By contrast,
hippocampal neurons incubated with Aβ oligomers in the presence of
rapamycin displayed similar synaptic activity to control neurons
(Fig. 4B,C; control 0.36 ± 0.08 Hz; Aβ 0.08 ± 0.02 Hz; Aβ+ rapamycin
0.33 ± 0.05 Hz; rapamycin 0.65 ± 0.07 Hz). These results indicate that10
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Fig. 2. Chronic treatment with rapamycin increases the frequency of intracellular calcium transients. (A) Representative ﬂuorimetric recordings obtained from control hippocampal
neurons and rapamycin-treated hippocampal neurons (48 h; 1 μM). (B) Effect of rapamycin (RAP) on the frequency (Hz) of intracellular Ca2+ transients obtained from the indicated num-
ber of neurons. Bars are mean ± SEM. *** p b 0.001 (Student t-test).
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against synaptic failure induced by Aβ oligomers.
4. Discussion
Rapamycin, amacrolide antibiotic, is known to act by noncompetitive
inhibition of the TORC1 complex, a crucial serine–threonine kinase
which regulates several cellular processes [33]. Recent evidence shows
that rapamycin was effective at increasing the lifespan in mice even
though treatment began at 600 days of age [10]. Since there are several
pathologies associated with aging and the fact that aging is, by far, the
greatest risk factor for most neurodegenerative diseases, it would be
interesting to know if the increase in lifespan is correlated with an in-
creased mental health status. The aim of our study was to determine
the effect of chronic rapamycin treatments in mature rat hippocampus
cultures (14–15 DIV). Our results showed that chronic application of
rapamycin increased the frequency of miniature postsynaptic currents,
but not the amplitude of the events, indicating a presynaptic site of ac-
tion. Recent evidence shows that autophagy, induced by the inhibition
of mTOR, was strongly activated in the hippocampus of rapamycin-
treated mice [16]. In agreement with our observations, previous studies
suggest that the effects of autophagy are primarily presynaptic [7,8],
and that mTOR-regulated autophagy has a synaptic role, speciﬁcally in
regulating neurotransmission [7]. These studies support our results,
and may suggest that the observed enhancement of presynaptic trans-
mission in mature hippocampal neurons by rapamycin may be a result
of the activation of autophagy.
The electrophysiological results were correlated with an increase in
the frequency of transient calcium currents. In agreement with these ob-
servations, Terashima et al. showed that the activity of a Ca2+-dependent
K+ channel was modulated by rapamycin through its direct association
with the FK506 binding protein-12 (FKBP12) which induced a signiﬁcant
increase in the open timeof the channel [34]. The increase in transient cal-
cium current frequency induced by rapamycin suggests that rapamycin
augmented the calcium-dependent exocytosis of synaptic vesicles.
Supporting the electrophysiological and calcium transient observations,
we found that rapamycin increased SV2 levels, which is a positive modu-
lator of calcium-dependent exocytosis [35]. In agreementwith our results,
previous studies showed that rapamycin leads to NMDA-dependent in-
duction of long-term potentiation (LTP) in CA1 neurons of rat hippocam-
pal slices when paired with weak presynaptic stimulation [36], improved
memory deﬁcits associated with cannabinoid consumption [37] and res-
cuedmemory deﬁcits in amousemodel of tuberous sclerosis inwhich the
mTOR pathway was hyperactivated [14]. It is important to highlight that
the effect of rapamycin is not restricted to disease models, but it is alsoobserved in wild type aged animals [10]. Furthermore, recent evidence
shows that rapamycin enhances cognitive function in young adult mice
and blocks age-associated cognitive decline in older animals [31]. This ev-
idence is consistent with our results, since we observed an improvement
in the neuronal network connectivity and function with rapamycin
treatment (Figs. 1; 2; 3).
Our results, taken togetherwith previous studies indicate thatmTOR
activity is required for local protein synthesis at synapses [3], suggest
that mTOR may have time-dependent effects on the regulation of syn-
aptic function. Our studies, performed after 48 h of mTOR inhibition,
suggest that sustained inhibition of mTOR activity in hippocampal
neurons in culture enabled enhanced synaptic transmission [5,6,36]. Be-
cause TOR is a conserved Ser/Thr kinase that regulates cell growth and
metabolism in response to environmental cues (insulin/IGF, cell energy
status, nutrients and stress) via different signaling transduction path-
ways [33], it is possible that inhibition of mTOR may affect synaptic
function in different ways, not only at different times during synaptic
activation, but also in a manner dependent on speciﬁc culture condi-
tions such as local rapamycin concentrations and age of cultured
neurons, among other factors.
An important issue related with aging is the prevalence of age-
related diseases like AD. It is not clear how the inhibition of mTOR
could have neuroprotective effects. In this regard, it is well known
that mTOR is important in the regulation of protein synthesis [2,4],
which is critical for synaptic plasticity and memory consolidation [4].
In this context, studies have shown that inhibition of mTOR decreases
the late phase of long term potentiation (LTP) [4,6]. Also, there is evi-
dence showing that Aβ decreases the mTOR signaling [38,39], having
a toxic effect. Interestingly, Cammalleri et al. showed that there is a
time dependence of rapamycin sensitivity since the late long-term po-
tentiation (L-LTP) is sensitive to application of rapamycin only during
the induction paradigm,whereas rapamycin application after the estab-
lishment of L-LTP was ineffective [40]. On the other hand, several evi-
dence show beneﬁcial effects of rapamycin (i.e. extending the lifespan
in various species including mice) [10,41], as well as therapeutic bene-
ﬁts in experimental models of several age-linked neurodegenerative
diseases as AD [16,42]. Our results support the neuroprotective effect
described for rapamycin, since it prevents the synaptic failure induced
by Aβ oligomers (Fig. 4).
There is evidence that shows a relationship between brain seizures
and the incidence of Alzheimer's disease [43–45]. Palop et al. showed
that Aβ oligomers cause wide ﬂuctuations in the neuronal expression
of synaptic activity-regulated genes, as well as epileptiform activity
and nonconvulsive seizures [46,47]. They proposed that high levels of
Aβ induce aberrant excitatory neuronal activity and this activates
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which may contribute to AD-related network dysfunction [46]. Appar-
ently the epileptiform-like effect of Aβ is acute, since it has been
shown that Aβ induced a rapid increase in intracellular calcium and
miniature currents, indicating an enhancement in vesicular transmitter
release, which eventually leads to a blockage in neurotransmission by
vesicular depletion [20] leading to a synaptic loss. Related to this, sever-
al studies had reported a reduction in presynaptic proteins, such as
SNAP25, synaptophysin, synaptotagmin and SV2, in neuronal cultures
chronically treated with Aβ oligomers [20,28]. According to this, our
results showed a decrease in the levels of presynaptic SV2 proteins
and in synaptic activity of hippocampal neurons after chronic treatment
with Aβ oligomers (Fig. 4). Although there is evidence showing that theincrease in synaptic activity is associated with neurodegenerative ef-
fects [46,47], there is also evidence suggesting that synaptic activation
protects against Aβ-related synaptic alterations [48]. The intracellular
accumulation of Aβ oligomers is associated with early degeneration of
distal neurites and synaptic compartments [48,49]. Apparently the syn-
aptic activation by glycine-induced long-term potentiation (g-LTP) and
KCl-induced depolarization reduce the levels of intraneuronal Aβ [48].
Also, evidence has shown that moderate levels of NMDAR activity are
beneﬁcial for neurons [50]. For example, synaptic NMDAR activation in-
hibits the production of Aβ [51] and selective enhancement of synaptic
activity by low doses of NMDA interrupts Aβ-induced neurotoxicity
[52]. On the other hand, recent studies indicate that decreasing mTOR
signaling through the administration of rapamycin reduces Aβ levels
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with the same rapamycin-supplemented diet that extends lifespan
[10], blocked AD-like impairments in spatial learning and memory by
autophagy [16]. According to this evidence, our results suggest that
the chronic inhibition of mTOR with rapamycin induces an increase in
the synaptic activity which might protect against the synaptotoxity of
Aβ oligomers by regulating presynaptic components such as SV2
(Fig. 4).
Rapamycin is already used in clinical settings, and it has been previ-
ously shown that rapamycin crosses the blood–brain barrier [53], which
makes it an interesting drug for treating neurodegenerative diseases.
Therefore, our study sheds light on the use of rapamycin or rapamycin-
related compounds [54] in clinical trials, supporting the use of “enhancers
of presynaptic activity” as drugs for chronic conditions characterized by
sustained synaptic failure such as that in AD.
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